Are there generic versions of Platinib on the market?

As a highly selective RET tyrosine kinase inhibitor, Pralsetinib has played an important role in the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant thyroid cancer since its approval in 2020. Due to its strong targeting, relatively low side effects, and significant alleviation effect on cases resistant to traditional treatments, platinib has quickly become a hot drug in the international cancer treatment field. However, due to the high price of the original drug and the heavy financial burden on patients, the emergence of generic drugs of Platinib and its market accessibility have become the focus of clinical attention.

At present, positive signals for the first generic drug of Platinib have emerged globally. According to information from reliable overseas channels, a pharmaceutical company in Laos has successfully developed a generic version of Platinib and put it on the market. The specification of this generic drug is 100mg, 120 pills per bottle, and the price is about more than 3,000 yuan, which is far lower than the tens of thousands of yuan of the original drug. Although the price will be affected by exchange rate fluctuations and logistics costs, the economic accessibility brought by the overall price is undoubtedly good news for some patients.

From the perspective of drug composition, the active ingredients and dosage specifications of the generic version of platinib are basically the same as those of the original drug, and theoretically have similar bioavailability and efficacy. Although there is currently no public large-scale clinical equivalence trial data, feedback from clinical practice shows that some patients also achieve good control after using generic drugs, which have become an important alternative especially in resource-constrained countries and regions.

However, it needs to be emphasized that the generic version of platinib is currently only sold in Laos and has not yet been officially approved by other regions. Most of it is purchased through overseas self-purchase channels. Therefore, patients need to weigh multiple factors such as legality, safety and traceability during use. Professional doctors also recommend that before considering generic drugs, you must obtain drug information through formal channels and develop a treatment plan under the guidance of professional doctors.

Reference: https://gavreto.com/